Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30890059 | 0.80 | CDK1 (0.50) | CDK1LMNACYP3A4PMP22ALDH1A1 | |
| SCHEMBL2063240 | 0.80 | CDK1 (0.50) | CDK1LMNACYP3A4PMP22ALDH1A1 | |
| SCHEMBL26779059 | 0.79 | CDK1 (0.37) | CDK1LMNACYP3A4PMP22ALDH1A1 | |
| SCHEMBL25457076 | 0.77 | CDK1 (0.36) | CDK1LMNACYP3A4PMP22ALDH1A1 | |
| SCHEMBL12615857 | 0.77 | CDK1 (0.48) | CDK1LMNACYP3A4PMP22ALDH1A1 | |
| SCHEMBL29334076 | 0.76 | CDK1 (0.47) | CDK1LMNACYP3A4PMP22ALDH1A1 | |
| SCHEMBL26800760 | 0.74 | CDK1 (0.58) | CDK1LMNACYP3A4PMP22ALDH1A1 | |
| SCHEMBL6577461 | 0.73 | TLR7 (0.52) | LMNACYP3A4PMP22ALDH1A1MAPT | |
| SCHEMBL25457796 | 0.73 | CDK1 (0.36) | CDK1LMNACYP3A4PMP22ALDH1A1 | |
| SCHEMBL3286320 | 0.71 | RXFP1 (0.41) | CDK1LMNACYP3A4PMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-3912980-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | Minghui Pharmaceutical (Shanghai) Limited (CN) | 2021-11-24 | — | — | EP | disclosed |
| EP-3854799-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020147798-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | 明慧医药（上海）有限公司 | 2020-07-23 | — | — | WO | disclosed |
| WO-2020057546-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | 上海迪诺医药科技有限公司 | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | CDK1 180/4885LMNA 3364/4885CYP3A4 4049/4885 |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | CDK1 113/4885LMNA 3949/4885CYP3A4 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.